SOURCE: StockCall

StockCall

September 10, 2010 09:11 ET

Equity Research on VIVUS and Sequenom - The Biotech Battle on Obesity

JOHANNESBURG, SOUTH AFRICA--(Marketwire - September 10, 2010) -  www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on VIVUS Inc. (NASDAQ: VVUS) and Sequenom Inc. (NASDAQ: SQNM). Register with us today at www.stockcall.com/ to have free access to these researches. 

Biotechnology companies are growing increasingly competitive over two rapidly developing markets: obesity medication and DNA analysis technology. The obesity medication makers are developing drugs to stop an existing problem while DNA tech companies are looking to find new ways to prevent them. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on VIVUS Inc. and Sequenom Inc.; investors and shareholders of these companies can simply register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html

As U.S. obesity rates near 35 percent there is markedly increased competition in the biotech industry to develop drugs and get them approved by the Food and Drug Administration. FDA approval is significantly altering profit margins for drug makers. Essentially, the farther along a drug is in drug-trials determines how much a producer will bid to buy it. Drug testing trials for obesity medications have grown more demanding since Fen-phen was pulled from the market in 1997. VIVUS Inc. which in July had to digest negative FDA feedback on its obesity drug Qnexa will be looking forward for FDA approval decision date set on October 28, 2010. The company will first have to provide more long-term safety data regarding this drug which it expects to do in the quarter of 2010. VIVUS Inc. research report is accessible for free by registering today at www.stockcall.com/VVUS100910.pdf

Today, expecting parents are placing more emphasis on prenatal testing than any generation before them. The rising trend in testing is fueling growth and development for the makers of DNA analysis products like Sequenom Inc. Sequenom Inc. research report is available for free by signing up now at www.stockcall.com/SQNM100910.pdf

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information